YI, US68247Q2012

111 forms special committee to review buyout proposal for 111 stock

Published on 10/18/2026 at 13:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Three directors formed a committee on September 28, 2026. The review concerns 111 stock as second-quarter revenue fell 28.3 percent to RMB 2.3 billion.

Governance and operating figures

The board established a three-member special committee on September 28, 2026.
Second-quarter 2026 net revenue fell 28.3 percent to RMB 2.3 billion.
Marketplace service income grew 18.2 percent in the first half of 2026.

YI, US68247Q2012, Illustration mit AI erstellt.

111 stock is facing a strategic review after 111, Inc. established a three-member special committee on September 28, 2026, to assess a preliminary, non-binding buyout proposal dated September 16. The Yahoo Finance report carrying the PR Newswire release said the board had made no decision and offered no assurance that a definitive transaction would follow.

Three dates define the review

The sequence began on September 16, 2026, when the founders submitted a preliminary proposal valued at USD 4.52 per ADS, according to TradeFlock. On September 17, 2026, 111 reported second-quarter net revenue of RMB 2.3 billion, down 28.3 percent year over year. On September 28, 2026, the board formed the committee, which includes three independent directors.

What does the operating shift mean?

The latest results show a sharp revenue contraction alongside faster growth in selected platform activities. Second-quarter marketplace service income rose 18.2 percent in the first half of 2026, while promotional pharmaceutical revenue increased 121 percent to RMB 60.7 million, according to The Globe and Mail. The figures show why the committee review matters for investors: the proposed strategic change is taking place while 111 reshapes its revenue mix.

Cost control improved in the same reporting period. Total operating expenses fell 16.1 percent to RMB 155.5 million, and fulfillment expenses declined 29.5 percent to RMB 63.6 million. Gross segment profit was RMB 132.3 million, compared with RMB 185.4 million a year earlier, keeping profitability central to the strategic discussion.

Governance remains the next milestone

The committee's mandate covers the proposal and other strategic alternatives, but its formation does not represent an agreement. The company describes its business as a digital healthcare platform connecting consumers, pharmacies and pharmaceutical companies in China, with online retail, wholesale and healthcare services.